Solvotrin Therapeutics & Nuance Pharma Partner to Launch Ireland’s #1 Iron Brand, Active Iron, in China

SHANGHAI, January 7, 2026 - Solvotrin Therapeutics, a leading Irish healthcare developer, has officially announced an exclusive agreement with Nuance Pharma to distribute Active Iron in China. This partnership leverages Nuance Pharma’s robust commercial expertise in iron deficiency and women’s health to bring Ireland’s premier iron technology to a broader patient base. 

The announcement was made during a Consulate General of Ireland Business Dinner at the Fairmont Peace Hotel, held on the occasion of the visit of An Taoiseach, Mr. Micheál Martin T.D. The event was hosted by the Consul General of Ireland, Mr. David Murphy, alongside Enterprise Ireland, IDA Ireland, and Bord Bia. Key attendees included Pat O’Flynn (CEO) and Ronan McClafferty (COO) of Solvotrin Therapeutics, and Mark Lotter (CEO) and Eva Su (VP, Commercial Excellence) of Nuance Pharma. 

Pictured left to right: Pat O Flynn (Solvotrin Therapeutics), Mark Lotter (Nuance Pharma), Micheál Martin (Taoiseach), 

A Breakthrough in Iron Supplementation Developed in collaboration with Trinity College Dublin, Active Iron’s patented SCFA Protein Iron technology marks a major breakthrough. This clinically proven product is renowned for superior tolerability and efficacy, solving the long-standing challenges of "iron intolerance" and "absorption bottlenecks." By delivering iron directly to the most active site of absorption via a unique protein-protected formula, it maximizes uptake while significantly minimizing side effects like nausea and constipation. 

“We are pleased to announce this strategic partnership with Nuance,” said Pat O’Flynn, CEO of Solvotrin Therapeutics. “Nuance’s agile, innovation-led model makes them the ideal partner to introduce our trusted, clinically driven solutions to China. We also acknowledge the support of Enterprise Ireland in facilitating the initial engagement. Active Iron is now a leading brand across Europe and the United States, and we look forward to bringing a trusted, clinically driven solution to consumers in China.” 

Mark G. Lotter, CEO of Nuance Pharma, added: “Partnering with Solvotrin represents an exciting opportunity to address a broader spectrum of iron-related health needs, particularly in women’s health. We look forward to making this standout product accessible to patients across China.”